Showing 1 – 20 of 3304
Relevance | Newest | Oldest |
  • Association of Blood Pressure Lowering With Mortality and Cardiovascular Disease Across Blood Pressure Levels: A Systematic Review and Meta-analysis

    Abstract Full Text
    online first
    JAMA Intern Med. 2017; doi: 10.1001/jamainternmed.2017.6015

    This systematic review and meta-analysis assesses the association of treatment to lower blood pressure with death and cardiovascular disease at different blood pressure levels in randomized clinical trials.

  • Smoking Cessation Pharmacotherapy Among Smokers Hospitalized for Coronary Heart Disease

    Abstract Full Text
    JAMA Intern Med. 2017; 177(10):1525-1527. doi: 10.1001/jamainternmed.2017.3489

    This study uses data from the Premier Alliance database to assess factors associated with the use of smoking cessation pharmacotherapy in smokers hospitalized for coronary heart disease.

  • JAMA Internal Medicine October 1, 2017

    Figure 1: Unmet Need for Prescription Drugs Among Adults Insured Throughout Year 1

    Estimates from multivariable linear probability model controlling for the effects of age, sex, and race/ethnicity in year 1 and time-varying measures of household income as a percentage of the federal poverty line, self-reported health, and number of chronic conditions (coronary heart disease, angina, myocardial infarction, other heart disease, stroke, emphysema, high cholesterol, diabetes, arthritis, and asthma). Increase in unmet need for those losing health insurance in Year 2 was significantly greater than for the continuously insured.
  • JAMA Internal Medicine October 1, 2017

    Figure 2: Unmet Need for Prescription Drugs Among Adults Uninsured Throughout Year 1

    Estimates from multivariable linear probability model controlling for the effects of age, sex, and race/ethnicity in year 1 and time-varying measures of household income as a percentage of the federal poverty line, self-reported health, and number chronic conditions (coronary heart disease, angina, myocardial infarction, other heart disease, stroke, emphysema, high cholesterol, diabetes, arthritis, and asthma). Decrease in unmet need for those gaining health insurance in Year 2 was significantly greater than for the continuously uninsured.
  • JAMA Internal Medicine July 1, 2017

    Figure 2: All-Cause Mortality and Coronary Heart Disease (CHD) Deaths Plus Nonfatal Myocardial Infarction by Treatment Group (Pravastatin vs Usual Care) and Age

    A, C, and E, Shown is all-cause mortality by treatment group and age group. B, D, and F, Shown are CHD deaths plus nonfatal myocardial infarction by treatment group and age group. The hazard ratios (95% CIs) are listed in Table 2. Pravastatin was given as pravastatin sodium.
  • Sugar Industry and Coronary Heart Disease Research: A Historical Analysis of Internal Industry Documents

    Abstract Full Text
    JAMA Intern Med. 2016; 176(11):1680-1685. doi: 10.1001/jamainternmed.2016.5394

    This historical analysis uses internal sugar industry documents to describe how the industry sought to influence the scientific debate over the dietary causes of coronary heart disease in the 1950s and 1960s.

  • Food Industry Funding of Nutrition Research: The Relevance of History for Current Debates

    Abstract Full Text
    JAMA Intern Med. 2016; 176(11):1685-1686. doi: 10.1001/jamainternmed.2016.5400
  • Using Discordance in Monozygotic Twins to Understand Causality of Cardiovascular Disease Risk Factors

    Abstract Full Text
    JAMA Intern Med. 2016; 176(10):1530-1530. doi: 10.1001/jamainternmed.2016.4115
  • ω-3 Polyunsaturated Fatty Acid Biomarkers and Coronary Heart Disease: Pooling Project of 19 Cohort Studies

    Abstract Full Text
    free access
    JAMA Intern Med. 2016; 176(8):1155-1166. doi: 10.1001/jamainternmed.2016.2925

    This study evaluates biomarkers of seafood-derived eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid and plant-derived α-linolenic acid for incident coronary heart disease.

  • JAMA Internal Medicine August 1, 2016

    Figure 1: Relative Risk (RR) of Fatal Coronary Heart Disease (CHD) per 1-SD Increase in the Biomarkers α-Linolenic Acid (ALA; 18:3ω-3) and Eicosapentaenoic Acid (EPA; 20:5ω-3)

    Estimates were pooled using random effects meta-analysis. See eFigure 1 in the Supplement for results using inverse-variance weights. CHS indicates Cardiovascular Health Study; EPIC-Norfolk, European Prospective Investigation of Cancer (Norfolk); HPFS, Health Professionals Follow-up Study; KIHD, Kuopio Ischaemic Heart Disease Risk Factor Study; MCCS, Melbourne Collaborative Cohort Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS, Nurses’ Health Study; NSHDS, Northern Sweden Health and Disease Study; PHS, Physician’s Health Study; SCHS, Singapore Chinese Health Study; and ULSAM, Uppsala Longitudinal Study of Adult Men.
  • JAMA Internal Medicine August 1, 2016

    Figure 2: Relative Risk (RR) of Fatal Coronary Heart Disease (CHD) per 1-SD Increase in the Biomarkers Docosapentaenoic Acid (DPA; 22:5ω-3) and Docosahexaenoic Acid (DHA; 22:6ω-3)

    Estimates were pooled using random effects meta-analysis. See eFigure 1 in the Supplement for results using inverse-variance weights. CHS indicates Cardiovascular Health Study; EPIC-Norfolk, European Prospective Investigation of Cancer (Norfolk); HPFS, Health Professionals Follow-up Study; KIHD, Kuopio Ischaemic Heart Disease Risk Factor Study; MCCS, Melbourne Collaborative Cohort Study; MESA, Multi-Ethnic Study of Atherosclerosis; NHS, Nurses’ Health Study; NSHDS, Northern Sweden Health and Disease Study; PHS, Physician’s Health Study; SCHS, Singapore Chinese Health Study; SHHEC, Scottish Heart Health Extended Chart; and ULSAM, Uppsala Longitudinal Study of Adult Men.
  • Continuing Use of Prophylactic Percutaneous Coronary Intervention in Patients With Stable Coronary Artery Disease Despite Evidence of No Benefit: Déjà Vu All Over Again

    Abstract Full Text
    JAMA Intern Med. 2016; 176(5):597-598. doi: 10.1001/jamainternmed.2016.0600
  • Electrocardiography Evolution in a Woman Presenting With Alcohol Withdrawal Seizures and Cocaine Use

    Abstract Full Text
    JAMA Intern Med. 2016; 176(5):693-695. doi: 10.1001/jamainternmed.2016.0278
  • Wide Complex Tachycardia in a Patient With a History of Atrial Fibrillation

    Abstract Full Text
    JAMA Intern Med. 2016; 176(3):386-388. doi: 10.1001/jamainternmed.2015.7605
  • JAMA Internal Medicine October 1, 2015

    Figure: Statin Use in Very Elderly Individuals, 1999-2012

    Years are grouped into 2-year intervals (eg, 1999-2000). A, Percentages of very elderly individuals (>79 years) who reported a prescription for a statin from 1999 to 2012, by vascular disease. Primary prevention is defined as no history of previous coronary heart disease, stroke, or peripheral vascular disease. Secondary Prevention is defined as a history of coronary heart disease, stroke, or peripheral vascular disease. B, Percentage of very elderly individuals (>79 years) who reported a prescription for a statin reported by specific statin type (atorvastatin, lovastatin, pravastatin, rosuvastatin, and simvastatin) from 1999 to 2012. Individuals could be counted multiple times if they reported use of different drugs.
  • Informed Decision Making for Percutaneous Coronary Intervention for Stable Coronary Disease

    Abstract Full Text
    free access
    JAMA Intern Med. 2015; 175(7):1199-1206. doi: 10.1001/jamainternmed.2015.1657

    This cross-sectional analysis found that informed decision making is often incomplete in conversations between cardiologists and patients with stable angina.

  • Addressing Overuse of Medical Services One Decision at a Time

    Abstract Full Text
    JAMA Intern Med. 2015; 175(7):1092-1093. doi: 10.1001/jamainternmed.2015.1693

    This Editorial discusses overuse of medical services and proposes ways to assess and reduce patterns of overuse.

  • JAMA Internal Medicine June 1, 2015

    Figure: Hazard Ratios (HRs) of Coronary Heart Disease (CHD) Mortality, a First-Time CHD Event, and a First-Time Hard CHD Event per 1-mIU/L Higher Thyrotropin Level at Baseline, Adjusted for Age, Sex, and Smoking at Baseline

    The squares represent HRs from each cohort, and the lines represent 95% CIs. The diamonds represent pooled HRs (with 95% CIs) from random-effects (DerSimonian and Laird [D+L] Overall) and fixed-effect (inverse variance [I-V] Overall) meta-analysis. EPIC-Norfolk indicates European Prospective Investigation of Cancer–Norfolk; HUNT, Nord-Trøndelag Health Study; InCHIANTI, Invecchiare in Chianti; and PROSPER, Prospective Study of Pravastatin in the Elderly at Risk.aWeights are from random-effects analysis.
  • Thyroid Function Within the Normal Range and Risk of Coronary Heart Disease: An Individual Participant Data Analysis of 14 Cohorts

    Abstract Full Text
    free access
    JAMA Intern Med. 2015; 175(6):1037-1047. doi: 10.1001/jamainternmed.2015.0930

    This individual participant data analysis suggests that differences in thyroid function within the population reference range do not influence the risk of coronary heart disease.

  • Cardiovascular Disease After Hodgkin Lymphoma Treatment: 40-Year Disease Risk

    Abstract Full Text
    free access
    JAMA Intern Med. 2015; 175(6):1007-1017. doi: 10.1001/jamainternmed.2015.1180

    This retrospective cohort study found that Hodgkin lymphoma survivors are at high risk for cardiovascular diseases.